Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes
Tóm tắt
OBJECTIVE—The purpose of this study was to compare effects of insulin detemir once daily versus twice a day in a basal-bolus insulin regimen.
RESEARCH DESIGN AND METHODS—In this open-label, 7-month study, 520 patients with type 1 diabetes were randomly assigned to receive detemir once daily or twice daily with mealtime insulin aspart. Insulin doses were titrated over 1 month, with patients followed up over the subsequent 3 months. Thereafter, patients were able to switch from one regimen to the other, with an additional nonrandomized 3-month follow-up, to a total of 7 months. The primary end point was A1C at 4 months, with noninferiority defined as a difference <0.4% between groups.
RESULTS—A1C at 4 months was 8.1 ± 0.9 versus 8.0 ± 1.0% with once- and twice-daily detemir, respectively, with an adjusted between-group difference of 0.12% (95% CI −0.01 to 0.25%), showing noninferiority for once-daily dosing. Similar results were found in the per protocol population. Improvement in A1C was similar in both groups (−0.4 ± 0.8 vs. −0.5 ± 0.8%; P = 0.09, NS) but with differences in the 7-point glucose profile. Detemir doses were lower (29 ± 18 vs. 39 ± 20 units/day, P < 0.001), but aspart doses were higher (34 ± 17 vs. 26 ± 14 IU/day, P < 0.001) with once-daily detemir. At 7 months, A1C decreased slightly in patients switched from once-daily to twice-daily administration (8.2 ± 0.8 vs. 8.0 ± 0.8%; P = 0.34, NS) in association with increased total insulin doses (P < 0.05), but A1C increased in those switched from twice-daily to once-daily administration (7.2 ± 0.9 vs. 7.6 ± 0.8%, P < 0.05) in association with decreased doses (P < 0.05).
CONCLUSIONS—Although some individuals may benefit from twice-daily dosing, the most suitable routine starting schedule for detemir in a basal-bolus regimen for type 1 diabetes is once-daily injection.
Từ khóa
Tài liệu tham khảo
Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, Kurtzhals P: The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21: 1498–1504, 2004
Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR: A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28:1107–1112, 2005
Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620, 2004
Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F, Rønn B, Zdravkovic M, Pieber TR: Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 115:461–467, 2007
Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T: Albumin-bound basal insulin analogs (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 9:290–299, 2007
Heise T, Pieber TR: Towards peakless, reproducible and long-acting insulins: an assessment of the basal analogs based on isoglycemic clamp studies. Diabetes Obes Metab 9:648–659, 2007
Home P, Kurtzhals P: Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 7:325–343, 2006
Hermansen K, Davies M: Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 9:209–217, 2007
Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L: Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 61:523–528, 2007
DeVries JH, Nattrass M, Pieber TR: Refining basal insulin therapy: what have we learned in the age of analogs? Diabetes Metab Res Rev 23:441–454, 2007
Tsou HH, Hsiao CF, Chow SC, Yue L, Xu Y, Lee S: Mixed noninferiority margin and statistical tests in active controlled trials. J Biopharm Stat 17:339–357, 2007
Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J: Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 24:27–34, 2007
Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J: Effects of OD insulin detemir or neutral protamin hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus insulin regimen. Clin Ther 26:724–736, 2004
Albright ES, Desmond R, Bell DS: Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 27:632–633, 2004
Ashwell SG, Gebbie J, Home PD: Optimal timing of injection of once-daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times. Diabet Med 23:46–52, 2006
Ashwell SG, Gebbie J, Home PD: Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med 23:879–886, 2006
Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase PH: Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 66:49–56, 2004